Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02160626
Other study ID # A-101-SEBK-202
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 2014
Est. completion date December 2014

Study information

Verified date December 2018
Source Aclaris Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.


Description:

The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.

Each subject will have 4 target lesions on the trunk/extremities.

A further objective is to evaluate the safety and efficacy of two concentrations of A-101 solution and its matching vehicle when applied to SK target lesions on the trunk/extremities.


Recruitment information / eligibility

Status Completed
Enrollment 172
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject is at least 18 years of age

2. Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis

3. Subject has 4 appropriate seborrheic keratosis target lesions, as defined below, on the trunk/extremities:

- Have a clinically typical appearance

- Be treatment naïve

- Have a Physician Lesion Assessment (PLA) of =2

- Have a longest axis that is =7mm and =15mm

- Have a longest dimension perpendicular to the longest axis that is =7mm and =15mm

- Have a thickness that is =2mm

- Be a discrete lesion

- Be, when centered in the area outlined by the provided 3cm diameter circular template, the only seborrheic keratosis lesion present

- Not be in an intertriginous fold

- Not be in an area where clothing, such as a bra, might cause physical irritation

- Not be pedunculated.

4. If the subject is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an active form of birth control for the duration of the study

5. Subject is non-pregnant and non-lactating

6. Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of any target lesion or which exposes the subject to an unacceptable risk by study participation

7. Subject is willing and able to follow all study instructions and to attend all study visits

8. Subject is able to comprehend and willing to sign an Informed Consent Form (ICF).

Exclusion Criteria:

1. Subject has clinically atypical and/or rapidly growing seborrheic keratosis lesions

2. Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Leser-Trelat)

3. Subject has a current systemic malignancy

4. Subject has a history of keloid formation or hypertrophic scarring

5. Subject has used any of the following systemic therapies within the specified period prior to Visit 1:

- Retinoids; 180 days

- Glucocorticosteroids; 28 days

- Anti-metabolites (e.g., methotrexate); 28 days

6. Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to the target lesion, that in the investigator's opinion, interferes with the application of the study medication or the study assessments:

- LASER, light (e.g., intense pulsed light (IPL), photo-dynamic therapy (PDT)) or other energy based therapy; 180 days

- Retinoids; 90 days

- Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-fluorouracil, or ingenol mebutate; 60 days

- Glucocorticosteroids or antibiotics; 14 days

- Moisturizers/emollients, sunscreens; 12 hours

7. Subject currently has or has had any of the following within the specified period prior to Visit 1 on or in a proximity to the target lesion that, in the investigator's opinion, interferes with the application of the study medication or the study assessments:

- A cutaneous malignancy; 180 days

- Experienced a sunburn; 28 days

- A pre-malignancy (e.g., actinic keratosis); currently

- Body art (e.g., tattoos, piercing, etc.); currently

- Excessive tan; currently

8. Subject has a history of sensitivity to any of the ingredients in the study medications

9. Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations

10. Subject has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to Visit 1.

Study Design


Intervention

Drug:
A-101 Vehicle
Placebo control
A-101 (40) Topical Solution
A-101 (40) Topical Solution - high dose
A-101 (32.5) Topical Solution
A-101 (32.5) Topical Solution - low dose

Locations

Country Name City State
United States DermReseach, Inc. Austin Texas
United States Michigan Center for Research Corp. Clinton Township Michigan
United States The Education & Research Foundation, Inc. Lynchburg Virginia
United States Oregon Medical Research Center Portland Oregon
United States Gwinnett Clinical Research Center, Inc. Snellville Georgia

Sponsors (1)

Lead Sponsor Collaborator
Aclaris Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Per Subject Percentage Target Lesions Judged Clear by the Physician's Lesion Assessment (PLA) Mean of per-subject percentages of target lesions judged to be clear on the PLA (PLA = 0) at end of study (Visit 8). The PLA is a four point scale from 0 being clear to 3 being most severe lesion. Baseline, visit 8
Secondary Mean Change From Baseline to Visit 8 in the Physician's Lesion Assessment Change from baseline PLA will be calculated for each lesion first, then per-subject mean changes from baseline will be calculated.
The PLA is a score on a four scale from 0 to 3 with 0 being clear and 3 being the most severe, a lower score indicating a better result. For the mean change in this score, a larger mean change is a better result.
Baseline, visit 8
Secondary Proportion of Subjects Who Had at Least 3 of 4 Target Lesions Judged to be Clear on the Physician Lesion Assessment (PLA =0) at Visit 8. Proportion of Subjects who had at least 3 of 4 target lesions judged to be clear on the Physician Lesion Assessment (PLA =0) at visit 8. The PLA is a 4 point scale evaluating the severity of a lesion with 0 being clear and 3 being the most severe. Baseline, visit 8
See also
  Status Clinical Trial Phase
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT02260180 - Study of A-101 for the Treatment of Seborrheic Keratosis Phase 2
Completed NCT01214564 - Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis Phase 2
Active, not recruiting NCT05136144 - Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis Phase 2
Recruiting NCT06108024 - A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis Phase 2
Completed NCT06046144 - Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
Completed NCT03846531 - Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study N/A
Completed NCT03148691 - A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis Phase 2
Completed NCT03487588 - An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses Phase 4
Completed NCT00540566 - Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Completed NCT01159860 - Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses? N/A
Terminated NCT04688749 - Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
Completed NCT02667236 - A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. Phase 3
Completed NCT02667275 - A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis Phase 3
Completed NCT02667288 - An Open-Label Safety Study of A-101 Solution Phase 3
Completed NCT05353374 - Effectiveness of Sodium Fusidate Ointment Compared to Petrolatum for Wound Healing Following Cauterization N/A
Terminated NCT04249115 - Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study N/A